Association between genetic subgroups of pancreatic ductal adenocarcinoma defined by high density 500 K SNP-arrays and tumor histopathology

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Gutiérrez, María Laura ^a   Muñoz Bellvis, Luís ^b   del Mar Abad, Maríal ^b   Bengoechea, Oscar ^b   González González, María ^a   Orfao, Alberto ^a   Sayagués, José María ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CHROMOSOME; CHROMOSOME 10Q26.13; CHROMOSOME 10Q26.3; CHROMOSOME 11Q13.1; CHROMOSOME 11Q13.3; CHROMOSOME 11Q13.4; CHROMOSOME 12Q; CHROMOSOME 16Q24.1; CHROMOSOME 16Q24.3; CHROMOSOME 17P; CHROMOSOME 17P13.3; CHROMOSOME 18Q; CHROMOSOME 1P36.11; CHROMOSOME 1Q; CHROMOSOME 1Q21.1; CHROMOSOME 20Q; CHROMOSOME 22Q13.1; CHROMOSOME 22Q13.31; CHROMOSOME 22Q13.32; CHROMOSOME 2Q14.2; CHROMOSOME 3Q22.1; CHROMOSOME 6Q25.2; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME 9P22.1; CHROMOSOME 9P24.3; CHROMOSOME ABERRATION; CHROMOSOME XP22.33; CLINICAL ARTICLE; COPY NUMBER VARIATION; CYTOGENETICS; FEMALE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PANCREATIC DUCTAL ADENOCARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR DIFFERENTIATION; TUMOR GENE; CLASSIFICATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN CHROMOSOME; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; CYTOGENETICS; DNA COPY NUMBER VARIATIONS; FEMALE; GENES, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79960625621     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022315     Document Type: Article

References (46)

1. Harada T, Baril P, Gangeswaran R, Kelly G, Chelala C, et al. (2007) Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation. Br J Cancer 96: 373-382.
2. Nowak NJ, Gaile D, Conroy JM, McQuaid D, Cowell J, et al. (2005) Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 161: 36-50.
3. Harada T, Okita K, Shiraishi K, Kusano N, Kondoh S, et al. (2002) Interglandular cytogenetic heterogeneity detected by comparative genomic hybridization in pancreatic cancer. Cancer Res 62: 835-839.
4. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, et al. (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A 101: 9067-9072.
5. Harada T, Chelala C, Crnogorac-Jurcevic T, Lemoine NR, (2009) Genome-wide analysis of pancreatic cancer using microarray-based techniques. Pancreatology 9: 13-24.
6. Karhu R, Mahlamaki E, Kallioniemi A, (2006) Pancreatic adenocarcinoma-- genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer 45: 721-730.
7. LaFramboise T, (2009) Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 37: 4181-4193 gkp552 [pii];10.1093/nar/gkp552 [doi].
8. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, et al. (2008) Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27: 1951-1960.
9. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
10. Adsay NV, Basturk O, Bonnett M, Kilinc N, Andea AA, et al. (2005) A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol 29: 724-733.
11. Gutierrez ML, Sayagues JM, Del Mar AM, Bengoechea O, Gonzalez-Gonzalez, et al. (2011) Cytogenetic heterogeneity of pancreatic ductal adenocarcinomas: identification of intratumoral pathways of clonal evolution. Histopathology 58: 486-497 10.1111/j.1365-2559.2011.03771.x [doi].
12. Saldanha AJ, (2004) Java Treeview--extensible visualization of microarray data. Bioinformatics 20: 3246-3248 10.1093/bioinformatics/bth349 [doi];bth349 [pii].
13. Gorunova L, Johansson B, Dawiskiba S, ndren-Sandberg A, Jin Y, et al. (1995) Massive cytogenetic heterogeneity in a pancreatic carcinoma: fifty-four karyotypically unrelated clones. Genes Chromosomes Cancer 14: 259-266.
14. Gorunova L, Hoglund M, ndren-Sandberg A, Dawiskiba S, Jin Y, et al. (1998) Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer 23: 81-99.
15. Schleger C, Arens N, Zentgraf H, Bleyl U, Verbeke C, (2000) Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH). J Pathol 191: 27-32.
16. Heidenblad M, Schoenmakers EF, Jonson T, Gorunova L, Veltman JA, et al. (2004) Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines. Cancer Res 64: 3052-3059.
17. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117 nature09515 [pii];10.1038/nature09515 [doi].
18. Walker BA, Morgan GJ, (2006) Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. Clin Lymphoma Myeloma 7: 186-191.
19. Rodriguez JA, Li M, Yao Q, Chen C, Fisher WE, (2005) Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications. World J Surg 29: 297-305.
20. Grubbs EG, bdel-Wahab Z, Tyler DS, Pruitt SK, (2006) Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer. Ann Surg Oncol 13: 1645-1654.
21. Yagn WB, Cai F, Cheng CT, Cao G, Qin ZY, (2008) [Expression of prostate stem cell antigen and Claudin-4 in human pancreatic carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30: 728-731.
22. Adsay NV, Basturk O, Cheng JD, Andea AA, (2005) Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol 15: 254-264 S1053-4296(05)00033-0 [pii];10.1016/j.semradonc.2005.04.001 [doi].
23. Sung HY, Wu HG, Ahn JH, Park WY, (2010) Dcr3 inhibit p53-dependent apoptosis in gamma-irradiated lung cancer cells. Int J Radiat Biol 86: 780-790 10.3109/09553002.2010.484481 [doi].
24. Chen G, Luo D, (2008) Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci 113: 297-304 http://urn.kb.se/resolve?urn=urn:nbn:se:pub:diva-240 [pii].
25. Ho CH, Chen CL, Li WY, Chen CJ, (2009) Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 30: 1443-1451 bgp135 [pii];10.1093/carcin/bgp135 [doi].
26. Chen C, Zhang C, Zhuang G, Luo H, Su J, et al. (2008) Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Cancer Invest 26: 965-974 906932905 [pii];10.1080/07357900801975256 [doi].
27. Tsuji S, Hosotani R, Yonehara S, Masui T, Tulachan SS, et al. (2003) Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 106: 17-25.
28. Swift SL, Burns JE, Maitland NJ, (2010) Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res 70: 347-356 0008-5472.CAN-09-1252 [pii];10.1158/0008-5472.CAN-09-1252 [doi].
29. Dupouy S, Viardot-Foucault V, Alifano M, Souaze F, Plu-Bureau, et al. (2009) The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One 4: e4223 10.1371/journal.pone.0004223 [doi].
30. Gui X, Guzman G, Dobner PR, Kadkol SS, (2008) Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides 29: 1609-1615 S0196-9781(08)00185-X [pii];10.1016/j.peptides.2008.04.014 [doi].
31. Blebea J, Mazo JE, Kihara TK, Vu JH, McLaughlin PJ, et al. (2000) Opioid growth factor modulates angiogenesis. J Vasc Surg 32: 364-373 S0741-5214(00)91981-5 [pii];10.1067/mva.2000.107763b [doi].
32. Zagon IS, Donahue RN, McLaughlin PJ, (2009) Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol 297: R1154-R1161 00414.2009 [pii];10.1152/ajpregu.00414.2009 [doi].
33. Smith JS, Tachibana I, Allen C, Chiappa SA, Lee HK, et al. (1999) Cloning of a human ortholog (RPH3AL) of (RNO) Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus. Genomics 59: 97-101 10.1006/geno.1999.5864 [doi];S0888-7543(99)95864-0 [pii].
34. Wagsater D, Lofgren S, Zar N, Hugander A, Dimberg J, (2010) Pigment epithelium-derived factor expression in colorectal cancer patients. Cancer Invest 28: 872-877 10.3109/07357901003735675 [doi].
35. Zhou D, Cheng SQ, Ji HF, Wang JS, Xu HT, et al. (2010) Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 136: 1719-1727 10.1007/s00432-010-0830-y [doi].
36. Casagrande G, te KG, Basso G, (2006) The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica 91: 765-771.
37. Abiatari I, Gillen S, DeOliveira T, Klose T, Bo K, et al. (2009) The microtubule-associated protein MAPRE2 is involved in perineural invasion of pancreatic cancer cells. Int J Oncol 35: 1111-1116.
38. Wang Y, Zhou X, Zhu H, Liu S, Zhou C, et al. (2005) Overexpression of EB1 in human esophageal squamous cell carcinoma (ESCC) may promote cellular growth by activating beta-catenin/TCF pathway. Oncogene 24: 6637-6645 1208819 [pii];10.1038/sj.onc.1208819 [doi].
39. Kimura Y, Morita T, Hayashi K, Miki T, Sobue K, (2010) Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells. Cancer Res 70: 501-511 0008-5472.CAN-09-1469 [pii];10.1158/0008-5472.CAN-09-1469 [doi].
40. Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, et al. (2007) Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell 11: 133-146 S1535-6108(06)00379-5 [pii];10.1016/j.ccr.2006.11.022 [doi].
41. Mu X, Chang C, (2003) TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3. Prostate 57: 129-133 10.1002/pros.10282 [doi].
42. de Oliveira SI, Andrade LN, Onuchic AC, Nonogaki S, Fernandes PD, et al. (2010) Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. BMC Cancer 10: 200. 1471-2407-10-200 [pii];10.1186/1471-2407-10-200 [doi].
43. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A, (2008) Pancreatic carcinogenesis. Pancreatology 8: 110-125.
44. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA, (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249.
45. Huang dW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57 nprot.2008.211 [pii];10.1038/nprot.2008.211 [doi].
46. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: 3.